An expert panel discusses recent updates in the treatment of myeloproliferative neoplasms from ASCO 2022.
EP. 1: Myeloproliferative Neoplasms: Essential Thrombocythemia
Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.
EP. 2: Managing Patients with Essential Thrombocythemia
Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.
EP. 3: Myeloproliferative Neoplasms: Polycythemia Vera
Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.
EP. 4: Treatment Options for Polycythemia Vera
An overview of the treatment options for patients with polycythemia vera.
EP. 5: PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera
Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.
EP. 6: Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms
A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.
EP. 7: Myeloproliferative Neoplasms: Myelofibrosis
Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.
EP. 8: Risk Stratification for Myelofibrosis
The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.
EP. 9: Ruxolitinib in Myelofibrosis Treatment and the COMFORT Trials
A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.
EP. 10: New JAK Inhibitors in Myelofibrosis Treatment
Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.
EP. 11: Efficacy and Safety of JAK Inhibitors for Myelofibrosis
Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.
EP. 12: Momelotinib in Myelofibrosis Treatment: Updates from ASCO 2022
Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
EP. 13: Novel Agents Under Investigation for Myelofibrosis
The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
EP. 14: Management of Accelerated Phase Myeloproliferative Neoplasms
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
EP. 15: Clinical Scenario: A 67-Year-Old with Myelofibrosis
Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
EP. 16: Myelofibrosis Treatment Approaches after Disease Progression
A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
EP. 17: Clinical Scenario: A 74-Year-Old with Cytopenic Myelofibrosis
Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
EP. 18: The Future of Myeloproliferative Neoplasm Treatment
The panelists conclude their discussion by highlighting investigational agents to look forward to.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management
TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma
Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC
Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber